FEATURED VIDEO


Billionaire Eric Sprott backs up his prediction that gold will hit $2400 by next summer.

FINANCIAL AND BUSINESS VIDEOS

THIS MONTH'S ISSUE

In-Depth Look at Opko Health's Portfolio and Prospects
By Gary Cassady

OVERVIEW

Opko Health (NYSE: OPK) is a mid-cap pharmaceutical stock with several corporate growth strategies: clinical drugs, medical devices, and strategic acquisitions. Of particular interest to many investors is its CEO's systematic buyback of common stock in the open market, totaling over $23 million in buys for his personal account during the past year.

Because of Opko Health's multi-faceted approach to the pharmaceutical business, most casual investors are not able to quickly analyze the financial condition of Opko Health, nor are they able to write it off as a one trick pony, "FDA approval or nothing" investment. As this article will demonstrate, a cursory analysis of the company's financials cannot reveal the nuances of Opko Health's corporate initiatives, which range from cancer research to pocket-sized blood testers.

This article will help the reader to better understand this $1.4 billion company, its long-term prospects, as well as the benefits and risks of Opko Health common stock.

To read the article in its entirety, please login. If you are not yet a subscriber, click here to sign up.
LEAVE A COMMENT
You must be logged in to post a comment.